Opendata, web and dolomites

variaTECT SIGNED

A novel genetic assay for risk assessment of cognitive decline in Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 variaTECT project word cloud

Explore the words cloud of the variaTECT project. It provides you a very rough idea of what is the project "variaTECT" about.

platform    drafted    triple    amyloid    emission    progressively    dementia    individuals    market    generate    cytox    living    feasibility    variatect    polymorphism    person    pet    aging    subjects    nucleotide    85    10m    fluid    provides    collected    ad    clinical    obtain    labs    almost    tests    score    solutions    2030    snpfitrtm    people    array    single    genetic    accuracy    disease    proprietary    cognitive    mark    capacity    fast    scans    prevalent    tomography    brain    positron    primary    revenues    plasma    saliva    disorder    processed    cerebrospinal    worldwide    healthcare    46m    alzheimer    pieces    trials    stratify    data    save    risk    10k    deployment    innovation    multiple    beta    accurate    software    ivd    unresolved    strategy    detection    csf    blood    population    diagnostic    leads    probability    dysfunction    upgrade    chain    snp    supply    broad    figure    2050    patient    degeneration    initiated    vitro    device    puncture    lumbar    double    snpfitr    types    complete    plan    130k    extracted    dna    ce    snps   

Project "variaTECT" data sheet

The following table provides information about the project.

Coordinator
CYTOX LIMITED 

Organization address
address: 53 FOUNTAIN STREET
city: MANCHESTER
postcode: M2 2AN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.cytoxgroup.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTOX LIMITED UK (MANCHESTER) coordinator 50˙000.00

Map

 Project objective

Alzheimer’s Disease (AD) is the most prevalent cognitive disorder and progressively leads to complete brain dysfunction and degeneration. The number of people living with Alzheimer’s worldwide is now estimated at 46M, with this figure set to almost double by 2030 and more than triple by 2050 due to population aging. Current methods for early assessment of AD are based on detection of β-amyloid in the brain Positron Emission Tomography (PET) scans, blood plasma tests or in cerebrospinal fluid (CSF) (via lumbar puncture). However, these solutions present some unresolved issues for broad market deployment. Cytox has developed the variaTECT platform to stratify AD risk in individuals by using a fast, accurate, reliable and cost-effective way to generate specific genetic information. The variaTECT comprises a proprietary 130K single nucleotide polymorphism (SNP) variaTECT array and the proprietary SNPfitRTM software to analyse data generated from the array. DNA extracted from a patient’s blood or saliva sample is collected and analyzed on the variaTECT array. The primary genetic data are then processed by the SNPfitR software, which provides a risk score associated with the probability to develop AD. variaTECT has an 85% accuracy, it can save up to €10k person-year for the healthcare systems and it can generate new revenues (up to €10M) for genetic labs. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, Cytox will upgrade the array design to increase the number of SNPs and the SNPfitR software to stratify subjects into different dementia types. Production capacity will be increased up to 100,000 pieces per year. Multiple clinical trials will be then initiated to obtain CE mark as In-Vitro Diagnostic (IVD) device.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VARIATECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VARIATECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More